Remove 2001 Remove Patients Remove Specialization
article thumbnail

PM360 Announces 2023 Trailblazer Award Winners

PM360

Later in his career he transitioned to the agency side and launched Weisscom Partners in 2001, which ultimately evolved into Real Chemistry. Director US Marketing and Patient Engagement, argenx US, Inc. PRODUCT LAUNCH OF THE YEAR NEXTSTELLIS (Mayne Pharma and EVERSANA INTOUCH) RELAUNCH/REVITALIZATION OF THE YEAR VRAYLAR (AbbVie Inc.

article thumbnail

PM360 Announces 2023 Trailblazer Award Finalists

PM360

Each of their trailblazing efforts result in much more than personal or organization success, it results in better quality of life for patients, better care options for healthcare providers, and happier and healthier people around the world.” Director US Marketing and Patient Engagement, argenx US, Inc. Braun Medical, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Galit Zuckerman-Stark

Cadensee

And specifically, when I was exposed to the issue of pain, helping patients suffer less from pain or from the pain treatment for me, was a good and still is a great mission. And one physician told me that, asking a patient what his pain level is like asking the patient what his blood pressure level. It took some time.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Kyruus is revolutionizing healthcare with its data-driven system that makes it easier for healthcare system to match patients to appropriate providers. BondLink is a fintech company specializing in the municipal bond market. Founded 2001. million in funding. 101-250 employees. See open roles. Founded 2016. 11-50 employees. $12

Sales 76
article thumbnail

Rare Disease Day: Why raising awareness is essential for a fairer future

Pharmaceutical Technology

This often puts patients in difficult situations where they are passed between doctors until a correct diagnosis is reached. The process takes an average of four to nine years in high-income countries, a contributing factor behind the sad story that as many as 50% of Europe’s rare disease patients currently remain undiagnosed.